Emerging drugs for age-related macular degeneration

Abstract

Age-related macular degeneration (AMD) is a leading cause of blindness that until recently had no recognised drug treatment. In wet AMD, choroidal neovascularisation (CNV) causes a profound loss of central vision. CNV is a complex process in which tissue ischaemia and/or inflammation is thought to trigger production of angiogenic signal molecules. The release of VEGF appears to be particularly important. Verteporfin photodynamic therapy was the first drug therapy to be licensed for the treatment of some types of wet AMD. Other treatments directly targeting VEGF or other aspects of angiogenesis, such as pegaptanib, ranibizumab and anecortave acetate, have either recently been licensed or are in the advanced stages of development. These and other promising treatment options such as combination strategies are reviewed.

Keywords::

• age-related macular degeneration
• anecortave acetate
• anti-inflammatory
• anti-VEGF
• bevacizumab
• choroidal neovascularisation
• combination therapy
• dexamethasone
• pegaptanib
• photodynamic therapy
• ranibizumab
• reduced fluence
• steroid
• triamcinolone
• vascular endothelial growth factor
• verteporfin

Financial disclosure

QLT, Vancouver, Canada was involved in editorial and organisational work, specifically related to marketing predictions.